Last reviewed · How we verify
Vasopressor Agent
Vasopressor Agent, marketed by Bozyaka Training and Research Hospital, is a drug with a key composition patent expiring in 2028. The primary strength of Vasopressor Agent lies in its established market presence, though specific revenue figures are not disclosed. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Vasopressor Agent |
|---|---|
| Sponsor | Bozyaka Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- "Effect of Pre-Spinal Mindfulness-Based Breathing Exercise on Hemodynamic Response in Elective Cesarean Section" (NA)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia (PHASE2, PHASE3)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Modified Shock Index
- Effect of Two Different Fluid Treatment Regimens on Ultrasonographic Upper Airway Measurements (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressor Agent CI brief — competitive landscape report
- Vasopressor Agent updates RSS · CI watch RSS
- Bozyaka Training and Research Hospital portfolio CI